Abbott Laboratories (ABT) Stock: Q4 Revenue Hits $11.46B but Shares Drop 7.35%

TLDR

• Abbott beats earnings, yet shares slide 7.35% as key segments weaken

• Strong devices growth fails to offset Nutrition and Diagnostics slowdown

• Q4 revenue hits $11.46B, but soft demand drags stock lower

• Abbott eyes 2026 growth despite pressure in Nutrition and Diagnostics
• Solid EPS and guidance fail to stop sharp market selloff

Abbott (ABT) posted fourth-quarter revenue of $11.46 billion, yet the stock fell 7.35% during a sharp session decline. The company reported stronger earnings and steady momentum across several medical technology segments, and the update moved expectations toward 2026. Abbott faced pressure from weak Nutrition and Diagnostics results, which shaped market sentiment through the day.

Abbott Laboratories, ABT

Q4 Performance Strengthens Margins but Segment Trends Shift

Abbott delivered organic sales growth of 3% in the quarter, and the company lifted adjusted EPS by 12%. The firm increased its full-year revenue to $44.3 billion, and it expanded earnings through higher margins and disciplined cost controls. Abbott also reported lower Nutrition and Diagnostics volumes, which limited total growth.

The company posted $5.675 billion in Medical Devices revenue, and the segment grew more than 10% organically. Abbott reported double-digit increases across Electrophysiology, Heart Failure, and Rhythm Management, and Diabetes Care delivered strong performance. Continuous glucose monitor sales reached $2 billion, which supported overall device strength.

Diagnostics revenue declined 2.5% on a reported basis, and global trends remained uneven across markets. Abbott observed ongoing pressure from lower demand for rapid tests, and COVID-19 testing revenue dropped sharply. Core Laboratory Diagnostics expanded, and international demand offset some weakness in China.

Full-Year Results Show Steady Expansion and Clear 2026 Outlook

Abbott increased full-year organic sales by 5.5 percent, and the company recorded $5.15 adjusted EPS for 2025. The firm cited broad medical device growth through the year, and the portfolio benefited from new technology adoption in major markets. Abbott advanced regulatory programs that strengthened its long-term device pipeline.

The company maintained momentum in Established Pharmaceuticals, and the segment posted 7.4 percent organic growth. Abbott highlighted strong emerging market performance, and demand rose across Latin America, India and the Middle East. Branded generics showed stable expansion and supported international revenue consistency.

Nutrition revenue fell 8.9% in the quarter, and strategic price changes affected near-term trends. Abbott expects new product launches in 2026, and the changes aim to rebuild volume growth across global markets.The business completed earlier product line exits, which continued to affect annual comparisons.

Guidance, Acquisitions, and Strategic Moves Shape 2026 Expectations

Abbott projected 2026 organic sales growth of 6.5 to 7.5%, and the firm expects adjusted EPS of $5.55 to $5.80. The company plans to close the Exact Sciences acquisition in the second quarter, and the move will position Abbott in the cancer diagnostics market. Furthermore, regulatory approvals strengthened its Electrophysiology portfolio and enhanced competitive positioning.

The company received FDA approval for the Volt PFA System, and it also secured a CE Mark for the TactiFlex Duo catheter. Abbott signaled that these additions will support growth in global cardiac care markets, and leadership expects rising adoption. These devices expand energy-based treatment options for atrial fibrillation.

Abbott also issued its 408th consecutive quarterly dividend, and the firm extended its record of 54 annual increases. The board confirmed a payout of $0.63 per share, and the dividend will be paid in February. Although the stock dropped sharply, Abbott ended the year with stronger earnings, a deeper pipeline, and a clear strategic plan heading into 2026.

The post Abbott Laboratories (ABT) Stock: Q4 Revenue Hits $11.46B but Shares Drop 7.35% appeared first on CoinCentral.